Edge Rewrite
location Source code View original
// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a272080e0d3af689

Jump to content

SVN-015

Add links
From Wikipedia, the free encyclopedia
SVN-015
Clinical data
Other namesSVN015
Routes of
administration		Unspecified[1]
Drug classSerotonin–dopamine reuptake inhibitor (SDRI)

SVN-015 is a serotonin–dopamine reuptake inhibitor (SDRI) which is under development for the treatment of major depressive disorder (MDD) and substance-related disorders such as stimulant use disorder.[1][2][3][4][5] It produces antidepressant-like effects in rodents similarly to the selective serotonin reuptake inhibitor (SSRI) fluoxetine.[4] SVN-015 is being developed by Solvonis Therapeutics, whose chief scientific officer (CSO) is David Nutt, in collaboration with the National Institute on Drug Abuse (NIDA).[1][2][3][4][6] As of August 2026, the drug is in the preclinical research stage of development for all indications.[1][2][3][5][7] The chemical structure of SVN-015 does not yet appear to have been disclosed.[1] However, Solvonis Therapeutics has patented monoamine transporter modulators.[8][9][10]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 "SVN 015". AdisInsight. 5 August 2026. Retrieved 6 August 2026.
  2. 1 2 3 "Delving into the Latest Updates on SVN-015 with Synapse". Synapse. 9 April 2026. Retrieved 6 August 2026.
  3. 1 2 3 Lyall, Ian (6 August 2026). "US drug agency to fund further testing of Solvonis addiction candidate". Proactiveinvestors UK. Retrieved 6 August 2026.
  4. 1 2 3 "Expansion of SVN-015 into Depression Following Positive Preclinical Data". Investing News Network (INN). 28 January 2026. Retrieved 6 August 2026.
  5. 1 2 "SVN-015 Advances into Further NIDA-Funded Studies Following Encouraging Initial Screening". Investing News Network (INN). 6 August 2026. Retrieved 6 August 2026.
  6. ↑ "Psychedelic Companies Directory". Psychedelic Alpha. 9 August 2024. Retrieved 6 August 2026.
  7. ↑ "Psychedelic Drug Development Tracker". Psychedelic Alpha. Retrieved 6 August 2026.
  8. ↑ "Therapeutic aminoindane compounds and compositions". Google Patents. 11 May 2022. Retrieved 6 August 2026.
  9. ↑ "Bridged ring compounds and their therapeutic use as cns agents". Google Patents. 16 February 2023. Retrieved 6 August 2026.
  10. ↑ "1,3-benzodioxole esters and their therapeutic use". Google Patents. 19 January 2023. Retrieved 6 August 2026.
[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=SVN-015&oldid=1368068089"